에 대한 최신 뉴스 Arbutus Biopharma (NASDAQ:ABUS) 주식

Arbutus Biopharma

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Health Care

Legal

ABUS

MRNA

수요일 4월 3일, Arbutus Biopharma(NASDAQ:ABUS)의 주식은 회사가 법정에서 Moderna Inc(NASDAQ:MRNA)에 대한 소송을 제기할 권한을 부여받은 후 20% 이상 급등했다.



What Happened: Arbutus는 첫 소송에서 Moderna에 대해 클레임을 제기하는데 성공했는 데, 이 소송의 내용은 Moderna가 개발한 코로나 백신의 기반이 된

아르부투스 주식, 모더나와의 코로나 백신 특허 쟁송을 앞두고 급등

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

Macro Economic Events

News

Econ #s

Economics

USA Natural Gas Storage -223B Vs -270B Est.; -258B Prior

Deep-pocketed investors have adopted a bullish approach towards Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UBER usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Uber Technologies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $177,200, and 7 are calls, amounting to $349,980.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $58.0 and $105.0 for Uber Technologies, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Uber Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Uber Technologies's whale activity within a strike price range from $58.0 to $105.0 in the last 30 days. 
<h3>Uber Technologies Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737646234_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UBER</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.75</td>
<td>$8.65</td>
<td>$8.75</td>
<td>$67.50</td>
<td>$80.5K</td>
<td>2.6K</td>
<td align="right">93</td>
</tr>
<tr>
<td>UBER</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.46</td>
<td>$0.43</td>
<td>$0.44</td>
<td>$58.00</td>
<td>$62.7K</td>
<td>31</td>
<td align="right">0</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$3.85</td>
<td>$3.7</td>
<td>$3.79</td>
<td>$64.00</td>
<td>$60.7K</td>
<td>600</td>
<td align="right">162</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$5.55</td>
<td>$5.0</td>
<td>$5.52</td>
<td>$105.00</td>
<td>$55.2K</td>
<td>763</td>
<td align="right">100</td>
</tr>
<tr>
<td>UBER</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$5.55</td>
<td>$5.05</td>
<td>$5.55</td>
<td>$105.00</td>
<td>$54.3K</td>
<td>763</td>
<td align="right">198</td>
</tr>
</tbody>
</table>

<h3>About Uber Technologies</h3>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing technology. Uber operates in more than 70 countries, with more than 161 million users who order rides or food at least once a month.
Having examined the options trading patterns of Uber Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Uber Technologies</h3>
<ul>
<li>Currently trading with a volume of 3,037,562, the UBER's price is down by -0.53%, now at $67.46. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Uber Technologies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

UBER

Unpacking the Latest Options Trading Trends in Uber Technologies

Investors with a lot of money to spend have taken a bullish stance on Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Boeing.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 13%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $474,501, and 8 are calls, for a total amount of $387,253.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $230.0 for Boeing during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Boeing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Boeing's whale trades within a strike price range from $140.0 to $230.0 in the last 30 days. 
<h3>Boeing Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737646228_0_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$6.25</td>
<td>$6.0</td>
<td>$6.25</td>
<td>$177.50</td>
<td>$187.5K</td>
<td>695</td>
<td align="right">300</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$14.25</td>
<td>$13.35</td>
<td>$14.05</td>
<td>$230.00</td>
<td>$140.5K</td>
<td>108</td>
<td align="right">100</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$38.1</td>
<td>$36.2</td>
<td>$36.2</td>
<td>$195.00</td>
<td>$87.3K</td>
<td>230</td>
<td align="right">26</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$54.85</td>
<td>$53.5</td>
<td>$54.2</td>
<td>$150.00</td>
<td>$54.2K</td>
<td>1.5K</td>
<td align="right">10</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$10.45</td>
<td>$10.25</td>
<td>$10.35</td>
<td>$175.00</td>
<td>$48.6K</td>
<td>3.1K</td>
<td align="right">54</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
After a thorough review of the options trading surrounding Boeing, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Boeing</h3>
<ul>
<li>Trading volume stands at 816,504, with BA's price down by -0.51%, positioned at $173.9.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What Analysts Are Saying About Boeing</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $212.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Barclays upgrades its rating to Overweight with a revised price target of $210. 
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Boeing with a target price of $215. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Boeing, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding Boeing's Options Activity: What's the Big Picture?

WIIM

NVEC

NVE shares are trading lower after the company reported a year-over-year decrease in Q3 financial results.

Investors with a lot of money to spend have taken a bullish stance on MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MSTR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 40 uncommon options trades for MicroStrategy.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 37%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $3,030,315, and 31 are calls, for a total amount of $1,810,721.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $0.5 to $1080.0 for MicroStrategy over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for MicroStrategy options trades today is 2458.6 with a total volume of 40,713.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for MicroStrategy's big money trades within a strike price range of $0.5 to $1080.0 over the last 30 days.
<h3>MicroStrategy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737646223_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$667.85</td>
<td>$665.95</td>
<td>$666.24</td>
<td>$1050.00</td>
<td>$2.6M</td>
<td>0</td>
<td>146</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$73.0</td>
<td>$72.15</td>
<td>$73.0</td>
<td>$390.00</td>
<td>$262.8K</td>
<td>1.1K</td>
<td>39</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$380.0</td>
<td>$377.9</td>
<td>$378.95</td>
<td>$10.00</td>
<td>$113.6K</td>
<td>514</td>
<td>37</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/24/25</td>
<td>$5.3</td>
<td>$5.05</td>
<td>$5.15</td>
<td>$410.00</td>
<td>$111.7K</td>
<td>2.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$373.35</td>
<td>$371.2</td>
<td>$372.27</td>
<td>$10.00</td>
<td>$111.6K</td>
<td>514</td>
<td>16</td>
</tr>
</tbody>
</table>

<h3>About MicroStrategy</h3>
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.
After a thorough review of the options trading surrounding MicroStrategy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>MicroStrategy's Current Market Status</h3>
<ul>
<li>With a trading volume of 6,263,683, the price of MSTR is down by -0.46%, reaching $375.57.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>Expert Opinions on MicroStrategy</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $650.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Benchmark downgraded its action to Buy with a price target of $650. 
&#x2A; In a cautious move, an analyst from Benchmark downgraded its rating to Buy, setting a price target of $650. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MSTR

MicroStrategy Unusual Options Activity

e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) has outperformed the market over the past 5 years by 36.48% on an annualized basis producing an average annual return of 49.62%. Currently, e.l.f. Beauty has a market capitalization of $6.61 billion. 
Buying $100 In ELF: If an investor had bought $100 of ELF stock 5 years ago, it would be worth $765.38 today based on a price of $117.41 for ELF at the time of writing.
<h3>e.l.f. Beauty's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737646210_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

PGEN

Precigen shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $4 to $6.

For the quarter ended on October 31st, Salesforce reported that revenue grew 8% YoY to&nbsp;$9.44 billion, surpassing LSEG&rsquo;s consensus estimate of&nbsp;$9.34 billion.
Net income grew 25%&nbsp;YoY to $1.5 billion. Adjusted earnings of&nbsp;$2.41&nbsp;per share which came short of LSEG&rsquo;s estimate of&nbsp;$2.44.
Fiscal fourth quarter guidance
Salesforce guided for current quarter sales between $9.9 billion and $10.10 billion and earnings per share in the range between $2.57&nbsp;and&nbsp;$2.62.
Salesforce ended 2024 on a strong note as it continues its transformation journey.&nbsp;
Salesforce CEO Marc Benioff&nbsp;summed up the report&nbsp;as yet another quarter of exceptional financial performance across revenue, margin, cash flow, and cRPO, with&nbsp;the&nbsp;AI system for enterprises built into the Salesforce Platform being at the heart of its&nbsp;groundbreaking transformation.&nbsp;Salesforce&rsquo;s Agentforce is an example of so-called AI Agent technology, with such advanced chatbots believed to represent the next step after Microosft Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>)-backed OpenAI&rsquo;s ChatGPT.&nbsp;The recently launched&nbsp;Agentforce&rsquo; AI software platform or&nbsp;so-called agents stand for advanced generative AI tools that can do multistep, complex tasks on a user&rsquo;s behalf. Benioff described it as AI agents letting humans unite to transform all customer interactions, allowing human capital to be used where it really makes a difference, such as strategic work. Since Microsof-backed OpenAI launched ChatGPT, a wave of innovation followed. Microsoft alone has also invested billions to develop its own AI products, but there is a lot of of execution ahead, just like for Meta Platforms (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) and Google who also touted their efforts to make their AI assistants more productive. Moreover,&nbsp;Benioff even took a hit at Microsoft, saying that its Microsoft Copilot is overhyped, like all LLM-based generative AI assistants, in his effort to shift the conversation towards AI agents that are becoming increasingly important in the new era that is in the making.
All in all, the better than expected revenue and strong outlook fueled&nbsp;hopes for Salesforces much-hyped artificial intelligence strategy coming to fruition. In addition, Seeking Alpha reported that a survey of chief information officers by KeyBanc showed that&nbsp;IT budgets are poised to increase 3.9%&nbsp;YoY in 2025, which would benefit both Salesforce and Microsoft, among other players.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

MSFT

Salesforce's AI Agents Pivot Is Already Showing Results

Stifel analyst J. Bruce Chan maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Buy and lowers the price target from $156 to $153.

Price Target

Analyst Ratings

Stifel Maintains Buy on United Parcel Service, Lowers Price Target to $153

Benchmark analyst Kurt Hallead maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and lowers the price target from $40 to $35.

Benchmark Maintains Buy on Halliburton, Lowers Price Target to $35

Nano Nuclear shares are trading higher after the company announced it acquired a portfolio of patents.

Stifel analyst J. Bruce Chan maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Hold and raises the price target from $139 to $147.

TFII

Stifel Maintains Hold on TFI International, Raises Price Target to $147

Live Oak Bancshares are trading lower after the company reported worse-than-expected Q4 EPS results.

INBK

First Internet Bancorp shares are trading lower after the company reported a year-over-year decrease in Q4 adjusted EPS results.

Stifel analyst Bert Subin maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Hold and raises the price target from $28 to $31.

SNDR

Stifel Maintains Hold on Schneider National, Raises Price Target to $31

Stifel analyst J. Bruce Chan maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Hold and raises the price target from $443 to $529.

SAIA

Stifel Maintains Hold on Saia, Raises Price Target to $529

Shares of luxury apparel company Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>), are skyrocketing on Thursday.
P180, a newly established venture concentrating on <a href="https://www.benzinga.com/pressreleases/25/01/b43144635/p180-acquires-sun-capitals-majority-stake-in-vince-holding-corp">expanding growth and profitability</a> in luxury clothes, obtained a controlling interest in the firm.
Affiliates of Sun Capital Partners, Inc. executed the deal. The acquisition is expected to enhance the brand&#8217;s growth and boost its profitability.
As a result of this acquisition, Brendan Hoffman is scheduled to take over as CEO of Vince starting Feb. 3, 2025, pending the finalization of his employment terms.
David Stefko will step down from his role as Interim CEO. He will continue serving on the company's board. In addition, Matthew Garff resigned from the board in connection with the acquisition.
Also Read: <a href="https://www.benzinga.com/25/01/43156651/puma-sees-growth-in-q4-sales-warns-of-cost-cut-in-2025">PUMA Sees Growth In Q4 Sales, Warns Of Cost Cut In 2025</a>
&#8220;VNCE is the perfect partner for P180; the brand&#8217;s dominance in the luxury contemporary market aligns seamlessly with our acquisition strategy,&#8221; said Hoffman.
&#8220;In addition, as VNCE has evolved its operating model, we believe having access to the technology and team of CaaStle, founded by Christine Hunsicker, my co-founder at P180, will further advance the company&#8217;s momentum in driving improved profitability while enhancing its omni-channel experience.&#8221;
P180 has been actively expanding its portfolio, with the acquisition of VNCE being its third major transaction since its establishment in 2024. This follows the venture&#8217;s earlier investment in Altuzarra and its collaboration with the high-end retailer elysewalker.
In conjunction with the acquisition, Vince made a notable reduction in its debt. Its subsidiary, V Opco, LLC, renegotiated its credit agreement with Bank of America to support the acquisition and alleviate subordinated debt owed to SK Financial Services, an affiliate of Sun Capital.
V Opco paid $15 million to SK Financial, which resulted in a $20 million decrease in debt. Following the deal, P180 will hold approximately 65% of Vince, while Sun Capital's affiliates maintain around 2%.
Price Action: Vince Holding shares are trading higher by 81.3% at $4.241 at the last check Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42896999/mercedes-benz-expands-in-india-with-new-outlets-to-tap-growing-luxury-market-report">Mercedes-Benz Expands In India With New Outlets To Tap Growing Luxury Market</a></li>
</ul>
Image: Shutterstock

VNCE

Luxury Retailer Vince Holding Stock Spikes On Heels Of Sun Capital Deal, CEO Change

CIBC analyst Dean Wilkinson maintains Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with a Outperformer and raises the price target from $68 to $70.

CIBC Maintains Outperformer on Brookfield, Raises Price Target to $70

Stifel analyst J. Bruce Chan maintains RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) with a Hold and raises the price target from $26 to $27.

Stifel Maintains Hold on RXO, Raises Price Target to $27

TKO Group shares are trading higher after signing multi-year deals with SPRIBE to boost Aviator's global presence through WWE and UFC.

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $5.00. Ro...

Arbutus Biopharma: Promising Developments and Positive Outlook Boost Buy Rating

Chardan analyst Keay Nakae raised the firm's price target on Arbutus Biopharma (ABUS) to $5 from $4.50 and keeps a Buy rating on the shares. The fi...

Arbutus Biopharma price target raised to $5 from $4.50 at Chardan

Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) and increased the price target to $5....

Arbutus Biopharma's Promising Clinical Trial Results Lead to Buy Rating

Arbutus Biopharma (ABUS) has released an update. Arbutus Biopharma, a company specializing in treatments for chronic hepatitis B, is set to partici...

Arbutus Biopharma Highlights Hepatitis B Treatment Advances

Whitefort Capital Management, which is a long-term investor and the third largest shareholder of Arbutus (ABUS) Biopharma with an ownership interes...

Whitefort Capital sends letter to Arbutus Biopharma board of directors

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jefferies says vaccine stocks are higher due to bird flu headlines and the potential downstream revenue implications as investors "hope" for the CO...

Jefferies says Arbutus, Roivant may benefit from bird flu headlines

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

Arbutus expects to significantly reduce its net cash burn in 2025

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), retaining the price target of $5.00. ...

Arbutus Biopharma: Strategic Advancements and Strong Financial Outlook Support Buy Rating

BNTX

CVAC

ROIV

Press Releases

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Earnings

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Present at Jefferies London Healthcare Conference

Biotech

General

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus Provides 2025 Corporate and Financial Update

BRNS

HC Wainwright & Co.

Chardan Capital

Jefferies

JMP Securities

4월 3일 수요일, 아르부투스 바이오파마(Arbutus Biopharma) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) 주식은 회사가 법정에서 모더나 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)에 대한 소송을 제기할 허가를 받은 후 15% 이상 급등했다.
What Happened: 아르부투스는 모더나가 코로나 백신을 개발할 때 사용한 메신저 RNA 기술에 대한 특허 침해 사건을 2022년 2월에 처음 제기했다
참고 자료: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38076756/cathie-wood-says-tesla-is-biggest-ai-project-in-world-sees-convergence-of-3-key-technolo">Cathie Wood Says Tesla Is &#8216;Biggest AI Project&#8217; In World, Sees Convergence Of 3 Key Technologies Driving Stock To $2,000</a>
그러나 이후에 이 사건은 여러 기술적 문제와 용어에 대한 법적 분쟁에 엉켰다.
2023년 4월 항소 법원은 모더나의 편을 들었지만 지난 2월 특허 침해 청구를 다루는 사법 절차인 마크맨(Markman) 청문회에서 판사는 모더나를 상대로 제기된 두 가지 청구에 대해 의견이 분분했다.
그러나 수요일, 미국 델라웨어 지방 법원 판사 미첼 S. 골드버그(Mitchell S. Goldberg) 판사는 &#8220;포뮬레이션 중 mRNA의 최소 70% / 최소 80% / 약 90%가 부분적으로 완전히 구별된다&#8221;는 아르부투스의 주장을 허용했다. 지질 소포 안에 함유되어 있다."
기술적이긴 하지만 이는 아르부투스의 주장에서 중요한 승리였다.
랭글리 캐피털(Rangeley Capital)의 크리스 데무스(Chris DeMuth)는 시킹 알파(Seeking Alpha)에 <a href="https://seekingalpha.com/news/4086921-arbutus-biopharma-jumps-after-patent-victory-in-fight-with-moderna?feed_item_type=news">전했다:</a> &#8220;오늘 청구권 구성 순서는 분쟁 조건에 대한 Arbutus의 제안과 사실상 동일했다.&#8221;
&#8220;이것은 이제 모더나가 아르부투스의 조건에서 벌어질 소송에의해 직면하게 되는 큰 문제다. ABUS/ROIV가 우선적으로 노출되어 있음을 밝혀야겠다. 오늘의 판결은 우리가 이것이 유용한 지적재산권이며, ABUS가 성공적으로 이를 방어할 것이라는 주장과 일관성이 있다.&#8221;
이 사건이 언제 재판에 넘어가거나, 법원의 명령에 따라 언제 해결되는지는 알려져 있지 않다.
ABUS 주가 움직임: 수요일 아르부투스의 주가는 15.87% 상승한 2.92달러에 마감했다.
이제 읽어보세요: <a href="https://www.benzinga.com/markets/equities/24/04/38074584/crude-oil-climbs-to-5-month-high-in-q1-analysts-expect-high-prices-to-persist-in-q2">1분기에 원유 가격이 상승, 2분기에도 높은 가격 유지 전망</a>
Shutterstock의 이미지

Comments

Arbutus Biopharma

뉴스

에 대한 최신 뉴스 Arbutus Biopharma (NASDAQ:ABUS) 주식

목요일, 4월 04, 2024

뉴스

파트너 / 기고자

벤징가 글로벌